Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × AMG 337 × Gastrointestinal × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

NCT02096666 2021-12-28

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Amgen

Phase 1/2 Completed
11 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡